Singleron Biotechnologies and Macrogen Europe announce a strategic alliance

27 February 2023 | Monday | News


Singleron Biotechnologies and Macrogen Europe are happy to announce their collaboration to combine their strengths to provide first-class single cell multi-omics sequencing solutions.

Singleron Biotechnologies, a front-runner in single cell multi-omics analysis, and Macrogen Europe, a state-of-the-art sequencing provider of fast and reliable genome analysis services have announced their partnership. This alliance will leverage strength from both companies to provide researchers with comprehensive single cell multi-omic solutions.

Singleron Biotechnologies are an innovative single cell sequencing solution provider with a focus on molecular diagnostics and are dedicated to applying ground-breaking single cell analysis techniques in clinical diagnosis, drug development, and health management. Macrogen Europe have partnerships with leading providers with the latest and innovative technology to help scientist accelerate their genomics discoveries. Their vision embodies the idea of customizing sequencing services for any life science community that requires NGS and Sanger technology. Together this integrated partnership combines Singleron's expertise in single cell sequencing and Macrogen Europe's cutting-edge genomic services to help promote human health and enhance the development of precision medicine.

Recent discoveries in genetics have exposed the diverse and unique genetic profiles of individuals, which is evolving medicine to become increasingly personalised. This new relationship between Singleron and Macrogen Europe offers a synergistic approach to understand the multiple layers of cellular regulation and accelerate the development for personalised medicine.

News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close